Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
AbstractBackground. This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth fa
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
6 July 2017
|
| In: |
Annals of oncology
Year: 2017, Jahrgang: 28, Heft: 10, Pages: 2429-2435 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdx343 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1093/annonc/mdx343 Verlag, Volltext: https://academic-oup-com.ezproxy.medma.uni-heidelberg.de/annonc/article/28/10/2429/3926574 
|
| Verfasserangaben: | B. Schultheis, D. Reuter, M.P. Ebert, J. Siveke, A. Kerkhoff, W.E. Berdel, R. Hofheinz, D.M. Behringer, W.E. Schmidt, E. Goker, S. De Dosso, M. Kneba, S. Yalcin, F. Overkamp, F. Schlegel, M. Dommach, R. Rohrberg, T. Steinmetz, M. Bulitta, D. Strumberg |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580407250 | ||
| 003 | DE-627 | ||
| 005 | 20220814232720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180827s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdx343 |2 doi | |
| 035 | |a (DE-627)1580407250 | ||
| 035 | |a (DE-576)510407250 | ||
| 035 | |a (DE-599)BSZ510407250 | ||
| 035 | |a (OCoLC)1341017670 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schultheis, Beate |e VerfasserIn |0 (DE-588)1066228655 |0 (DE-627)817030395 |0 (DE-576)42568038X |4 aut | |
| 245 | 1 | 0 | |a Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer |b a multicenter, randomized phase IIb study |c B. Schultheis, D. Reuter, M.P. Ebert, J. Siveke, A. Kerkhoff, W.E. Berdel, R. Hofheinz, D.M. Behringer, W.E. Schmidt, E. Goker, S. De Dosso, M. Kneba, S. Yalcin, F. Overkamp, F. Schlegel, M. Dommach, R. Rohrberg, T. Steinmetz, M. Bulitta, D. Strumberg |
| 264 | 1 | |c 6 July 2017 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.08.2018 | ||
| 520 | |a AbstractBackground. This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth fa | ||
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 28(2017), 10, Seite 2429-2435 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer a multicenter, randomized phase IIb study |
| 773 | 1 | 8 | |g volume:28 |g year:2017 |g number:10 |g pages:2429-2435 |g extent:7 |a Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer a multicenter, randomized phase IIb study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdx343 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://academic-oup-com.ezproxy.medma.uni-heidelberg.de/annonc/article/28/10/2429/3926574 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180827 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 7 | ||
| 999 | |a KXP-PPN1580407250 |e 3023870810 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"subtitle":"a multicenter, randomized phase IIb study","title":"Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer","title_sort":"Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer"}],"language":["eng"],"recId":"1580407250","origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"6 July 2017"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1580407250"],"doi":["10.1093/annonc/mdx343"]},"physDesc":[{"extent":"7 S."}],"note":["Gesehen am 27.08.2018"],"relHost":[{"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer a multicenter, randomized phase IIb studyAnnals of oncology","id":{"issn":["1569-8041"],"zdb":["2003498-2"],"eki":["320428796"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedKey":"1990"}],"recId":"320428796","language":["eng"],"part":{"year":"2017","text":"28(2017), 10, Seite 2429-2435","volume":"28","extent":"7","pages":"2429-2435","issue":"10"},"title":[{"title_sort":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title":"Annals of oncology"}],"pubHistory":["1.1990 -"]}],"name":{"displayForm":["B. Schultheis, D. Reuter, M.P. Ebert, J. Siveke, A. Kerkhoff, W.E. Berdel, R. Hofheinz, D.M. Behringer, W.E. Schmidt, E. Goker, S. De Dosso, M. Kneba, S. Yalcin, F. Overkamp, F. Schlegel, M. Dommach, R. Rohrberg, T. Steinmetz, M. Bulitta, D. Strumberg"]},"person":[{"display":"Schultheis, Beate","role":"aut","given":"Beate","family":"Schultheis"},{"display":"Hofheinz, Ralf-Dieter","given":"Ralf-Dieter","role":"aut","family":"Hofheinz"}]} | ||
| SRT | |a SCHULTHEISGEMCITABIN6201 | ||